Switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors-finally caught the right wave?

Transplantation

Volumn 92, Issue 7, 2011, Pages 728-730

  Naesens, Maarten ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MOUTH ULCER; NEPHROTOXICITY; NOTE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA;

ADRENAL CORTEX HORMONES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS; WITHHOLDING TREATMENT;

EID: 80053313905     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822d0994     Document Type: Note

References (28)

1. -2009 OPTN/SRTR Annual Report. Transplant data 1999-2008: Immunosuppression use for maintenance by regimen one year following transplantation, 1998 to 2007 recipients with kidney transplants. UNOS; Arbor Research Collaborative for Health, 2011. Available at: http://www.ustransplant. org/annual-reports/current/. Accessed June 15, 2011.
2. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28: 153.
3. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006; 70: 1019.
4. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
5. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
6. Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: De novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1.
7. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009; 373: 1235.
8. Oberbauer R. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus. Transplantation 2009; 87: S7.
9. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
10. Heilman R, Younan K, Wadei HM, et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 2011; 92: 767.
11. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837.
12. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
13. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175.
14. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115.
15. Pankewycz O, Leca N, Kohli R, et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: A prospective, protocol biopsy-guided study. Transplant Proc 2011; 43: 519.
16. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
17. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011; 11: 693.
18. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468.
19. Ekberg H, van Gelder T, Kaplan B, et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation 2011;92:82-87.
20. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
21. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
22. Sellares J, De Freitas DG, Mengel M, et al. Inflammation lesions in kidney transplant biopsies: Association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489.
23. Matas AJ. Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant 2011; 11: 687.
24. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
25. Schold JD, Kaplan B. The elephant in the room: Failings of current clinical endpoints in kidney transplantation. Am J Transplant 2010; 10: 1163.
26. Lachenbruch PA, Rosenberg AS, Bonvini E, et al. Biomarkers and surrogate endpoints in renal transplantation: Present status and considerations for clinical trial design. Am J Transplant 2004; 4: 451.
27. Bertele' V, Buonocore C, Michelacci F, et al. Efficacy and safety of immunosuppressive drugs approved in EU through the centralised procedure. Eur J Clin Pharmacol 2007; 63: 707.
28. Budde K, Arns W, Sommerer C, et al. Improved renal function of an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 years follow-up of the ZEUS trial [abstract]. Am J Transplant 2011; 11(suppl 2): 66.